financetom
Business
financetom
/
Business
/
New York Community Bancorp Expects Gains from Recent Sale of Loan Portfolios, Annual Report Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
New York Community Bancorp Expects Gains from Recent Sale of Loan Portfolios, Annual Report Says
Mar 14, 2024 10:24 AM

01:06 PM EDT, 03/14/2024 (MT Newswires) -- New York Community Bancorp ( NYCB/PU ) recently sold a commercial co-operative loan and a portfolio of consumer loans with a net book value of $899 million as part of efforts to revitalize its balance sheet after identifying material weaknesses with how it assessed loan risks, the bank said on Thursday.

The Feb. 29 sale of a commercial co-operative loan and the March 13 sale of consumer loans were disclosed Thursday by New York Community Bancorp ( NYCB/PU ) in its delayed Form 10-K annual report for 2023. Both transactions will be recorded by the bank in its current quarter ending March 31 and are expected to generate a net gain, it said.

NYCB said on March 1 it found material weaknesses with its internal loan reviews resulting from "ineffective oversight, risk assessment and monitoring activities." The disclosure sent its stock price reeling and left the bank scrambling to shore up its teetering finances, including a $1.05 billion sale last week of its common and preferred stock to a group of investors as well as cutting its quarterly dividend payments by 94% to $0.01 per share.

Overall, NYCB recorded a $112 million net loss available to common stockholders, or $0.16 per share, for the 12 months ended Dec. 31, compared with net income of $1.26 per share a year ago. The 2023 loss reflects a $2.4 billion goodwill impairment on the value of its loan portfolios during its Q4 partially offset by a $2.1 billion bargain gain on its purchase of Signature Bank earlier in 2023, it said.

NYCB shares were down 0.5% in recent Thursday trading.

Price: 3.73, Change: -0.02, Percent Change: -0.51

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intel Issued 'Subseasonal' H2 Revenue Guidance Amid Challenging Markets, AMD Competition, Wedbush Says
Intel Issued 'Subseasonal' H2 Revenue Guidance Amid Challenging Markets, AMD Competition, Wedbush Says
Aug 2, 2024
10:45 AM EDT, 08/02/2024 (MT Newswires) -- Intel ( INTC ) provided a subseasonal H2 revenue guidance which it attributed to more difficult end markets and expected loss of market share to Advanced Micro Devices ( AMD ) in the personal computer and server segments, Wedbush said in a note emailed Friday. The company said a nearly 400-basis-point drop in...
Lexicon Pharmaceuticals Files $200 Million Mixed Shelf
Lexicon Pharmaceuticals Files $200 Million Mixed Shelf
Aug 2, 2024
10:45 AM EDT, 08/02/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $200 million of its securities from time to time. The filing covers common and preferred shares, debt securities, warrants, rights, and units. Net proceeds from any such sale will...
Gunvor's head of US gasoline trading Sinenko departs for rival
Gunvor's head of US gasoline trading Sinenko departs for rival
Aug 2, 2024
NEW YORK, Aug 2 (Reuters) - Dmitri Sinenko, head of U.S. gasoline trading and executive committee member at Gunvor, is leaving the Swiss trader to join Russian rival Litasco, two sources familiar with the move said on Friday. Sinenko, widely considered one of the top gasoline traders, was poached by Gunvor from Noble Group at the end of 2017 as...
Amylyx Pharmaceuticals' Receives EU Orphan Designation for Potential Wolfram Syndrome Drug
Amylyx Pharmaceuticals' Receives EU Orphan Designation for Potential Wolfram Syndrome Drug
Aug 2, 2024
10:50 AM EDT, 08/02/2024 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said Friday it has received orphan drug designation from the European Commission for AMX0035 as a potential treatment for Wolfram syndrome. The designation was granted following a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products, the company said. Amylyx said it expects to report...
Copyright 2023-2026 - www.financetom.com All Rights Reserved